- Two subjects of interest in 1992 homicide to take polygraph tests (1/15/17)8
- Obama shortens sentence of inmate from Cape (1/19/17)9
- Business notebook: Jackson salon owner also opens a clothing store (1/16/17)
- Area hospitals hope a box helps prevent infant deaths (1/19/17)6
- Cape SportsPlex contractor offers a look at the project (1/15/17)14
- Meat-processing plant faces $70K penalty for Clean Water Act violations (1/17/17)4
- Southeast to lose $3.5 million from state in budget cuts (1/18/17)21
- Subjects of interest in 1992 killing take polygraph tests; results not revealed (1/18/17)2
- Governor cuts $146 million, colleges take hit (1/17/17)
- Southern Bank announces merger with Capaha Bank (1/15/17)
FDA requires new labels on HRT products
WASHINGTON -- The government announced new warnings Wednesday on the labels for hormone replacement therapies and advised millions of post-menopausal women to consult their doctors about whether to continue treatment.
The Food and Drug Administration acted after reviewing data from a landmark study that found that the increased risk of heart disease and breast cancer from using therapies combining the hormones estrogen and progestin far outweighed any health benefits. The government abruptly halted that study last July.
The FDA approved new labels for Wyeth Pharmaceuticals that includes a new boxed warning highlighting the increased risk for heart disease, heart attacks, strokes and breast cancer. They also include a reference to the study findings.
The new labels also emphasize that these products are not approved for the prevention of heart disease.
The FDA also said it was asking all manufacturers of estrogen and estrogen-progestin products to add similar warnings and change the enclosed patient information leaflet because all hormone products are believed to carry similar health risks.